CPIX (Cumberland Pharmaceuticals) ROCE %: -31.87% (As of Mar. 2026)

What is Cumberland Pharmaceuticals ROCE %?

Cumberland Pharmaceuticals CPIX +12.50% 32 ROCE % is -31.87% as of Mar. 2026. GuruFocus rates CPIX with a GF Score™ of 32/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cumberland Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -31.87%.

Cumberland Pharmaceuticals (NAS:CPIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cumberland Pharmaceuticals ROCE % Related Terms

Cumberland Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Cumberland Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cumberland Pharmaceuticals ROCE % Chart

Cumberland Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-8.04

-7.71

-9.51

-11.99

-5.51

Cumberland Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															12.84	-5.61	-17.16	-12.53	-31.87

32GF Score

Cumberland Pharmaceuticals Inc CPIX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cumberland Pharmaceuticals ROCE % Calculation

Cumberland Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-2.315	/	( ( (75.583 - 31.622)	+	(76.824 - 36.745) )	/ 2 )
	=	-2.315	/	( (43.961	+	40.079)	/ 2 )
	=	-2.315	/	42.02
	=	-5.51 %

Cumberland Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-12.204	/	( ( (76.824 - 36.745)	+	(70.995 - 34.488) )	/ 2 )
	=	-12.204	/	( ( 40.079	+	36.507 )	/ 2 )
	=	-12.204	/	38.293
	=	-31.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -31.87% mean?

Cumberland Pharmaceuticals (CPIX) has a ROCE % of -31.87% as of Mar. 2026.

Is Cumberland Pharmaceuticals' ROCE % too high?

Cumberland Pharmaceuticals' current ROCE % is -31.87%. Overall, Cumberland Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Cumberland Pharmaceuticals' ROCE % compare to CTOR and INCR?

Cumberland Pharmaceuticals' ROCE % of -31.87% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current ROCE % is -31.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cumberland Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.75 — trading 212.5% above its estimated fair value. The current ROCE % is -31.87%. Cumberland Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current ROCE % is -31.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued. The current stock price of $6.75 is trading 212.5% above its estimated GF Value™ of $2.16. GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CPIX:

ROCE %: -31.87%
GF Value™: $2.16 vs. price of $6.75 (212.5% above fair value)
GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cumberland Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CTOR INCR BGM SCYX ETST INIS TLPH IXHL ZYBT BTAI XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address 1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203

Website https://www.cumberlandpharma.com

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.

32GF Score

Get the complete analysis for CPIX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75

Price

$2.16

GF Value

View CPIX Analysis

See ROCE % data for all stocks →